No Data
The reevaluation of the Hong Kong stock Technology sector reveals that the Innovative Drugs sector is also expected to迎迎迎 DeepSeeK moment.
① Hong Kong stocks in the Biomedical sector are strengthening in the short term, which Bullish factors are worth paying attention to? ② The number of new drugs under research in our country has jumped to second in the Global ranking, what new support does the policy provide?
The era of large models in medicine! AI empowers the Industry to press the "accelerator", while the industry still hopes for revolutionary technology to emerge | Medicine Bottoming Series ④
① AI, with its powerful data summarization capabilities, is driving further innovation in the Medical and pharmaceutical fields; ② however, pharmaceutical companies still feel troubled about how to leverage AI in research and development; ③ industry insiders believe that the limitations of technology and the inviolability of ethical and legal responsibilities objectively prevent AI from having the capability to be a responsible entity.
Hong Kong stock Concept tracking | BEIGENE has become the domestic "leader in Innovative Drugs". Institutions are Bullish on the valuation recovery of Innovative Drugs in 2025 (with associated Concept stocks).
On February 21, BEIGENE surpassed Jiangsu Hengrui Pharmaceuticals with a market cap difference of 2.7 billion yuan, becoming the "big brother of innovative drugs."
Hong Kong stock market news | INNOVENT BIO (01801) rose over 7% in the afternoon. The application for the combination therapy of Sindilimab for cancer has been submitted for listing. The new drug IBI3002 has been approved for clinical trials.
INNOVENT BIO (01801) rose over 7% in the afternoon, as of the time of this report, it has increased by 5.82%, priced at 42.7 Hong Kong dollars, with a trading volume of 0.437 billion Hong Kong dollars.
The enthusiasm for pharmaceutical companies going public in Hong Kong continues! Two leading COVID-19 drug companies are entering the market. How can they break the dilemma of single revenue sources?
In the past three months, nearly 20 pharmaceutical companies have submitted listing applications to the Hong Kong Stock Exchange, including True Biologics and Wangshan Wangshui, two former stars in the COVID-19 pharmaceutical industry; the primary revenue of these two companies is still concentrated on products related to COVID-19 authorization or commercialization, which has significantly declined, providing limited Cash / Money Market.
BOCOM INTL: There is significant room for recovery in the mainland pharmaceutical Sector, and the foreign investment environment is expected to improve.
Subsequent bullish policies for finance and medical insurance/commercial insurance are expected to continue to be introduced, and the overall valuation of the sector remains at a historical low, indicating significant room for recovery in the sector, thus giving the mainland pharmaceutical Industry a "leading" rating.
